Medicure to Present Financial Results on August 21, 2025 Call at 8:30 am ET for Quarter Ended June 30, 2025
Medicure (OTC:MCUJF), a pharmaceutical company focused on the US healthcare market, has scheduled its Q2 2025 financial results conference call for August 21, 2025, at 8:30 AM ET. The company will file its Q2 2025 financial statements after market close on August 20, 2025.
The conference call will be accessible via toll-free and international dial-in numbers, with a participant access code of 850331. A live webcast will be available, and management will conduct a Q&A session following the presentation. A recording will be made available on the company's website after the event.
Medicure (OTC:MCUJF), azienda farmaceutica rivolta al mercato sanitario statunitense, ha programmato la conference call sui risultati finanziari del secondo trimestre 2025 per il 21 agosto 2025 alle 8:30 AM ET. La società presenterà i bilanci del Q2 2025 dopo la chiusura dei mercati il 20 agosto 2025.
La conference call sarà raggiungibile tramite numeri verdi e internazionali, con codice di accesso partecipanti 850331. Sarà disponibile anche una webcast in diretta e la direzione terrà una sessione di domande e risposte al termine della presentazione. Una registrazione sarà pubblicata sul sito web dell’azienda dopo l’evento.
Medicure (OTC:MCUJF), compañía farmacéutica enfocada en el mercado sanitario de EE. UU., ha programado su conferencia telefónica sobre resultados financieros del segundo trimestre de 2025 para el 21 de agosto de 2025 a las 8:30 AM ET. La empresa presentará sus estados financieros del Q2 2025 tras el cierre del mercado el 20 de agosto de 2025.
La conferencia será accesible mediante números gratuitos y números internacionales, con código de acceso para participantes 850331. Habrá una retransmisión en directo por webcast y la dirección realizará una sesión de preguntas y respuestas después de la presentación. Se publicará una grabación en la web de la compañía una vez finalizado el evento.
Medicure (OTC:MCUJF), 미국 의료 시장� 대상으� 하는 제약사인 본사� 2025� 2분기 실적 컨퍼런스 콜을 2025� 8� 21� 오전 8� 30�(동부시간)으로 예정했습니다. 회사� 2025� 8� 20� � 마감 � Q2 2025 재무제표� 공시합니�.
컨퍼런스 콜은 국내 무료전화 � 국제 전화� 접속 가능하�, 참가� 접속 코드번호� 850331입니�. 실시� 웹캐스트가 제공되며 발표 � 경영진과� 질의응답 시간� 있을 예정입니�. 이벤� 종료 � 회사 웹사이트� 녹음본이 게시됩니�.
Medicure (OTC:MCUJF), société pharmaceutique axée sur le marché de la santé aux États-Unis, a programmé sa conférence téléphonique sur les résultats financiers du deuxième trimestre 2025 le 21 août 2025 à 8h30 (heure de l’Est). Les états financiers du T2 2025 seront déposés après la clôture des marchés le 20 août 2025.
La conférence téléphonique sera accessible via des numéros gratuits et internationaux, avec le code d’accès participants 850331. Un webcast en direct sera proposé et la direction organisera une session de questions-réponses après la présentation. Un enregistrement sera mis en ligne sur le site de la société après l’événement.
Medicure (OTC:MCUJF), ein Pharmaunternehmen mit Fokus auf den US-Gesundheitsmarkt, hat seine Telefonkonferenz zu den Finanzergebnissen für das zweite Quartal 2025 für den 21. August 2025 um 8:30 Uhr ET angesetzt. Die Q2-2025-Abschlüsse werden nach Börsenschluss am 20. August 2025 eingereicht.
Die Telefonkonferenz ist über gebührenfreie und internationale Einwahlnummern erreichbar; der Teilnehmerzugangscode lautet 850331. Zudem steht ein Live-Webcast zur Verfügung, und das Management führt nach der Präsentation eine Fragerunde durch. Eine Aufzeichnung wird nach der Veranstaltung auf der Firmenwebsite bereitgestellt.
- None.
- None.
WINNIPEG, MB / / August 18, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present Financial Results for the quarter ended June 30, 2025 via conference call on August 21, 2025 at 8:30 am Eastern Time. The Financials for the quarter ended June 30, 2025 will be filed after market close on August 20, 2025.
Conference Call Info:
Topic: Medicure's Q2 2025 Results
Call date: Thursday, August 21, 2025
Time: 7:30 AM Central Time (8:30 AM Eastern Time)
Toll Free: 1 (888) 506-0062
International: 1 (973) 528-0011
Participant Access Code: 850331
Webcast: This conference call will be webcast live over the internet at the following link: https://www.webcaster4.com/Webcast/Page/2965/52887
You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company's website.
About Medicure Inc.
Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc. ("Marley Drug"), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving access to medications for all Americans together with exceptional customer service and free home delivery. Medicure also operates Gateway Medical Pharmacy ("Gateway"), located in Portland, Oregon in a medical office building near major transportation lines and multiple healthcare clinics and centers. In addition to regular customers, the pharmacy services multiple long-term care facilities and provides non-sterile compounding services. Medicure also operates West Olympia Pharmacy ("West Olympia"), located in Olympia, Washington in a medical office complex near multiple clinics. For more information visit . For more information about Medicure please visit . For additional information about AGGRASTAT®, please visit or refer to the full . For additional information about ZYPITAMAG®, please visit or refer to the full
To be added to Medicure's e-mail list, please visit:
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review voucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its current Form 20F.
AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks.
For more information, please contact:
Dr. Albert D. Friesen
Chief Executive Officer
Tel. 888-435-2220
Fax 204-488-9823
E-mail: [email protected]
SOURCE: Medicure, Inc.
View the original on ACCESS Newswire